🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

18 results for “Lundbeck” Clear

  1. Bifeprunox

    H. Lundbeck A/S

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  2. Eptinezumab

    H. Lundbeck A/S

    Migraine

    phase 3 small molecule completed

    1 trial

  3. Lu AF35700

    H. Lundbeck A/S

    Treatment-resistant Schizophrenia

    phase 3 small molecule terminated

    1 trial

  4. VYEPTI 100 mg concentrate for solution for infusion

    H. Lundbeck A/S

    Migraine

    phase 3 small molecule active

    1 trial

  5. VYEPTI 100 mg concentrate for solution for infusion

    H. Lundbeck A/S

    Chronic migraine

    phase 3 small molecule active

    1 trial

  6. VYEPTI 100 mg concentrate for solution for infusion, Nacl 0.9%

    H. Lundbeck A/S

    Migraine

    phase 3 small molecule active

    1 trial

  7. commercially available saline solution for infusion, Amlenetug 53 mg/ml solution for infusion

    H. Lundbeck A/S

    Multiple System Atrophy

    phase 3 small molecule active

    1 trial

  8. A Phase II, multi-site, open-label, dose-titration trial to investigate the safety, tolerability, pharmacokinetics, and efficacy of Lu AG13909 in adults with Cushing’s disease

    H. Lundbeck A/S

    Cushing's Disease

    phase 2 other active

    1 trial

  9. Lu AA34893

    H. Lundbeck A/S

    Depression in Patients With Bipolar Disorder

    phase 2 small molecule terminated

    1 trial

  10. Lu AE58054

    H. Lundbeck A/S

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  11. Melperone HCl

    Lundbeck Australia Pty Ltd

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  12. Placebo to match IMP Lu AG09222

    H. Lundbeck A/S

    Migraine

    phase 2 small molecule active

    1 trial

  13. A study to test the safety and tolerability of Lu AH69593 in adults that are healthy or have narcolepsy.

    H. Lundbeck A/S

    Narcolepsy

    phase 1 other active

    1 trial

  14. A trial to test the safety and tolerability of Lu AH70212 and Lu AH69593 in healthy adults.

    H. Lundbeck A/S

    Narcolepsy

    phase 1 other active

    1 trial

  15. Interventional, open-label, single-group, long-term follow-up trial of Lu AG22515 in patients with moderate-to-severe Thyroid Eye Disease

    H. Lundbeck A/S

    Active, moderate-to-severe TED

    phase 1 other active

    1 trial

  16. Lu AF28996

    H. Lundbeck A/S

    Parkinson Disease

    phase 1 small molecule active

    1 trial

  17. Lu AF28996 in Patients With Parkinson's Disease

    H. Lundbeck A/S

    Parkinson's Disease

    phase 1 other active

    1 trial

  18. VYEPTI 100 mg concentrate for solution for infusion

    H. Lundbeck A/S

    Chronic Migrane, Migrane, Medication Overuse Headache

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources